<document>
 <table id="Table 1">
  <caption text="

   Drug name, clinical indication and FDA/EMA approval reported in the review.
  
">
  </caption>
  <legend text="

   FDA, Food and Drug Administration; IL, interleukin; IL-17RA, IL-17 receptor A; CD, Cluster of Differentiation; PsO, psoriasis PsA, psoriatic arthritis; AS, Ankylosing Spondylitis; RA, Rheumatoid Arthritis; CD, Crohn's Diseases; UC, Ulcerative Colitis.
  
">
  </legend>
  <row row="0">
   <cell col-end="0" col-start="0" row-end="0" row-start="0" text="Drug name">
   </cell>
   <cell col-end="1" col-start="1" row-end="0" row-start="0" text="Target">
   </cell>
   <cell col-end="2" col-start="2" row-end="0" row-start="0" text="FDA approval date and indication">
   </cell>
   <cell col-end="3" col-start="3" row-end="0" row-start="0" text="EMA approval date and indication">
   </cell>
   <cell col-end="4" col-start="4" row-end="0" row-start="0" text="Ongoing trials">
   </cell>
  </row>
  <row row="1">
   <cell col-end="0" col-start="0" row-end="1" row-start="1" text="Secukinumab">
   </cell>
   <cell col-end="1" col-start="1" row-end="1" row-start="1" text="IL-17A">
   </cell>
   <cell col-end="2" col-start="2" row-end="1" row-start="1" text="2015 PsO, 2016 PsA and AS">
   </cell>
   <cell col-end="3" col-start="3" row-end="1" row-start="1" text="2015 PsO, 2016 PsA e AS">
   </cell>
   <cell col-end="4" col-start="4" row-end="1" row-start="1" text="/">
   </cell>
  </row>
  <row row="2">
   <cell col-end="0" col-start="0" row-end="2" row-start="2" text="Ixekizumab">
   </cell>
   <cell col-end="1" col-start="1" row-end="2" row-start="2" text="IL-17A">
   </cell>
   <cell col-end="2" col-start="2" row-end="2" row-start="2" text="2016 PsO, 2017 PsA, 2019 AS">
   </cell>
   <cell col-end="3" col-start="3" row-end="2" row-start="2" text="2018 PsO, 2019 PsA">
   </cell>
   <cell col-end="4" col-start="4" row-end="2" row-start="2" text="Phase III AS">
   </cell>
  </row>
  <row row="3">
   <cell col-end="0" col-start="0" row-end="3" row-start="3" text="Brodalumab">
   </cell>
   <cell col-end="1" col-start="1" row-end="3" row-start="3" text="IL17-RA (IL-17A, IL-17E, IL-17F)">
   </cell>
   <cell col-end="2" col-start="2" row-end="3" row-start="3" text="2017 PsO">
   </cell>
   <cell col-end="3" col-start="3" row-end="3" row-start="3" text="Not approved">
   </cell>
   <cell col-end="4" col-start="4" row-end="3" row-start="3" text="Phase II PsA">
   </cell>
  </row>
  <row row="4">
   <cell col-end="0" col-start="0" row-end="4" row-start="4" text="Bimekizumab">
   </cell>
   <cell col-end="1" col-start="1" row-end="4" row-start="4" text="IL-17A, IL-17F">
   </cell>
   <cell col-end="2" col-start="2" row-end="4" row-start="4" text="Not approved">
   </cell>
   <cell col-end="3" col-start="3" row-end="4" row-start="4" text="Not approved">
   </cell>
   <cell col-end="4" col-start="4" row-end="4" row-start="4" text="Phase II PsA
     
     Phase II AS">
   </cell>
  </row>
  <row row="5">
   <cell col-end="0" col-start="0" row-end="5" row-start="5" text="Ustekinumab">
   </cell>
   <cell col-end="1" col-start="1" row-end="5" row-start="5" text="p40 subunit of IL12 and IL23">
   </cell>
   <cell col-end="2" col-start="2" row-end="5" row-start="5" text="2009 PsO, 2013 PsA, 2016 CD">
   </cell>
   <cell col-end="3" col-start="3" row-end="5" row-start="5" text="2009 PsO,
     
     2013 PsA,
     
     2018 CD">
   </cell>
   <cell col-end="4" col-start="4" row-end="5" row-start="5" text="/">
   </cell>
  </row>
  <row row="6">
   <cell col-end="0" col-start="0" row-end="6" row-start="6" text="Guselkumab">
   </cell>
   <cell col-end="1" col-start="1" row-end="6" row-start="6" text="p19 subunit of IL23">
   </cell>
   <cell col-end="2" col-start="2" row-end="6" row-start="6" text="2017 PsO">
   </cell>
   <cell col-end="3" col-start="3" row-end="6" row-start="6" text="2017 PsO">
   </cell>
   <cell col-end="4" col-start="4" row-end="6" row-start="6" text="Phase II PsA">
   </cell>
  </row>
  <row row="7">
   <cell col-end="0" col-start="0" row-end="7" row-start="7" text="Tildrakizumab">
   </cell>
   <cell col-end="1" col-start="1" row-end="7" row-start="7" text="p19 subunit of IL23">
   </cell>
   <cell col-end="2" col-start="2" row-end="7" row-start="7" text="2018 PsO">
   </cell>
   <cell col-end="3" col-start="3" row-end="7" row-start="7" text="2018 PsO">
   </cell>
   <cell col-end="4" col-start="4" row-end="7" row-start="7" text="Phase II PsA">
   </cell>
  </row>
  <row row="8">
   <cell col-end="0" col-start="0" row-end="8" row-start="8" text="Risankizumab">
   </cell>
   <cell col-end="1" col-start="1" row-end="8" row-start="8" text="p19 subunit of IL23">
   </cell>
   <cell col-end="2" col-start="2" row-end="8" row-start="8" text="2019 PsO">
   </cell>
   <cell col-end="3" col-start="3" row-end="8" row-start="8" text="2019 PsO">
   </cell>
   <cell col-end="4" col-start="4" row-end="8" row-start="8" text="Phase III PsA
     
     Phase II AS">
   </cell>
  </row>
  <row row="9">
   <cell col-end="0" col-start="0" row-end="9" row-start="9" text="Tofacitinib">
   </cell>
   <cell col-end="1" col-start="1" row-end="9" row-start="9" text="JAK1/JAK3">
   </cell>
   <cell col-end="2" col-start="2" row-end="9" row-start="9" text="2012 RA, 2017 PsA, 2018 UC">
   </cell>
   <cell col-end="3" col-start="3" row-end="9" row-start="9" text="2017 RA, 2018 PsA, 2018 UC">
   </cell>
   <cell col-end="4" col-start="4" row-end="9" row-start="9" text="Phase II/III AS">
   </cell>
  </row>
  <row row="10">
   <cell col-end="0" col-start="0" row-end="10" row-start="10" text="Upadacitinib">
   </cell>
   <cell col-end="1" col-start="1" row-end="10" row-start="10" text="JAK1">
   </cell>
   <cell col-end="2" col-start="2" row-end="10" row-start="10" text="2019 RA">
   </cell>
   <cell col-end="3" col-start="3" row-end="10" row-start="10" text="2019 RA">
   </cell>
   <cell col-end="4" col-start="4" row-end="10" row-start="10" text="Phase II PsA
     
     Phase II AS
     
     Phase II Axial nr-SpA">
   </cell>
  </row>
  <row row="11">
   <cell col-end="0" col-start="0" row-end="11" row-start="11" text="Filgotinib">
   </cell>
   <cell col-end="1" col-start="1" row-end="11" row-start="11" text="JAK1">
   </cell>
   <cell col-end="2" col-start="2" row-end="11" row-start="11" text="Not approved">
   </cell>
   <cell col-end="3" col-start="3" row-end="11" row-start="11" text="Not approved">
   </cell>
   <cell col-end="4" col-start="4" row-end="11" row-start="11" text="Phase II PsA
     
     Phase II AS">
   </cell>
  </row>
  <row row="12">
   <cell col-end="0" col-start="0" row-end="12" row-start="12" text="Abatacept">
   </cell>
   <cell col-end="1" col-start="1" row-end="12" row-start="12" text="CD80 and CD86 receptors">
   </cell>
   <cell col-end="2" col-start="2" row-end="12" row-start="12" text="2005 RA, 2017 PsA">
   </cell>
   <cell col-end="3" col-start="3" row-end="12" row-start="12" text="2017 PsA">
   </cell>
   <cell col-end="4" col-start="4" row-end="12" row-start="12" text="/">
   </cell>
  </row>
  <row row="13">
   <cell col-end="0" col-start="0" row-end="13" row-start="13" text="CF101">
   </cell>
   <cell col-end="1" col-start="1" row-end="13" row-start="13" text="A3 adenosine receptor">
   </cell>
   <cell col-end="2" col-start="2" row-end="13" row-start="13" text="Not approved">
   </cell>
   <cell col-end="3" col-start="3" row-end="13" row-start="13" text="Not approved">
   </cell>
   <cell col-end="4" col-start="4" row-end="13" row-start="13" text="/">
   </cell>
  </row>
  <row row="14">
   <cell col-end="0" col-start="0" row-end="14" row-start="14" text="ABT-122">
   </cell>
   <cell col-end="1" col-start="1" row-end="14" row-start="14" text="TNF and IL-17A">
   </cell>
   <cell col-end="2" col-start="2" row-end="14" row-start="14" text="Not approved">
   </cell>
   <cell col-end="3" col-start="3" row-end="14" row-start="14" text="Not approved">
   </cell>
   <cell col-end="4" col-start="4" row-end="14" row-start="14" text="Phase II PsA">
   </cell>
  </row>
  <statements>
   <statement id="1" text="Ongoing trials are differentiated into Phase III AS, Phase II AS, Phase II PsA, Phase III PsA and Phase II Axial nr-SpA." type="entailed">
   </statement>
   <statement id="2" text="The ASAS-EULAR recommendations for the management of patients with spondylarthritis are dated back to 2016 [ 96 ] and since then there have been major advances in pharmacological treatments, including old and new pathogenic mechanisms used as therapeutic targets." type="entailed">
   </statement>
   <statement id="3" text="The FDA approval date ranges from 2001 to 2020." type="refuted">
   </statement>
   <statement id="4" text="There are 14 types of drug names given in the table." type="entailed">
   </statement>
   <statement id="5" text="There are 18 types of drug names given in the table." type="refuted">
   </statement>
   <statement id="6" text="There are 5 different types of columns." type="entailed">
   </statement>
  </statements>
 </table>
</document>